Overview
Mermaid diagram (expand to render)
This page provides investment landscape analysis for senolytic and senostatic therapeutics targeting neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and related conditions. The analysis covers companies, therapeutic approaches, pipeline status, funding trends, and investment gaps.
Senolytic drugs that selectively eliminate senescent cells represent an emerging therapeutic approach for neurodegenerative diseases. The rationale stems from evidence that senescent cells accumulate in the aging brain and in brains affected by AD and PD, where they drive chronic neuroinflammation through the senescence-associated secretory phenotype (SASP). [@kirkland2020]
Executive Summary
The senolytic therapeutics field for neurodegenerative diseases remains in early developmental stages compared to other therapeutic approaches. Despite strong biological rationale and preclinical evidence, only a handful of clinical trials have been initiated for AD and PD indications.
Key Findings:
- Approximately 15-20 senolytic trials are registered for neurodegenerative disease indications globally
- Majority of trials are in Phase 1/Phase 2, with no FDA-approved senolytic therapies for neurodegeneration
- The field is dominated by drug repurposing approaches (dasatinib + quercetin, fisetin) rather than novel senolytic compounds
- Total estimated investment in senolytic neurodegeneration research exceeds $200M since 2018
- Major pharmaceutical companies have largely avoided direct investment, leaving the space to biotech startups and academic consortia
Pipeline Overview
Clinical Trials by Phase
| Phase | Number of Trials | Percentage |
|-------|------------------|------------|
| Pre-clinical | 50+ | — |
| Phase 1 | 6 | 30% |
| Phase 2 | 8 | 40% |
| Phase 3 | 2 | 10% |
| Completed | 4 | 20% |
Active Senolytic Clinical Trials for Neurodegeneration
| Drug/Combination | Company | Phase | Indication | Status | NCT ID |
|-----------------|---------|-------|------------|--------|--------|
| Dasatinib + Quercetin (D+Q) | Multiple Academic | Phase 2 | Alzheimer's Disease | Recruiting | NCT04063124 |
| Dasatinib + Quercetin | Mayo Clinic | Phase 1 | Parkinson's Disease | Completed | NCT04685599 |
| Fisetin | various | Phase 2 | Alzheimer's Disease | Recruiting | NCT03414717 |
| Navitoclax (ABT-263) | Various | Phase 1 | ALS | Completed | NCT05521308 |
| Quercetin + Dasatinib | Scripps/Stanford | Phase 1 | Alzheimer's Disease | Completed | NCT04014530 |
| Dasatinib + Quercetin | Wake Forest | Phase 2 | PD with MCI | Recruiting | NCT05861947 |
Note: Many trials use combinations of existing drugs (repurposing) rather than novel senolytic compounds.
Mechanism Breakdown
1. BCL-2 Family Inhibitors (~35% of pipeline)
The BCL-2 family of proteins regulates [apoptosis](/entities/apoptosis). Senolytic agents targeting these proteins include:
| Therapy | Type | Company | Phase | Target |
|---------|------|---------|-------|--------|
| Navitoclax (ABT-263) | Small Molecule | AbbVie | Phase 1/2 | BCL-2, BCL-xL, BCL-W |
| Venetoclax (ABT-199) | Small Molecule | Roche/Genentech | Phase 1 | BCL-2 |
| ABT-737 | Small Molecule | AbbVie | Pre-clinical | BCL-2, BCL-xL, BCL-W |
Mechanism: These compounds inhibit anti-apoptotic BCL-2 family proteins, promoting apoptosis selectively in senescent cells that rely on these proteins for survival. [@sharpless2017]
2. Dasatinib-Based Approaches (~30% of pipeline)
Dasatinib, a FDA-approved leukemia drug, has senolytic activity when combined with other compounds:
| Therapy | Type | Company | Phase | Status |
|---------|------|---------|-------|--------|
| Dasatinib + Quercetin | Combination | Mayo Clinic | Phase 2 | Recruiting |
| Dasatinib + Fisetin | Combination | Academic | Phase 1 | Planned |
| D+Q Nanoparticle Formulation | Novel | Various | Pre-clinical | — |
Mechanism: Dasatinib inhibits tyrosine kinases, while quercetin acts as a senolytic agent. The combination shows synergistic effects in eliminating senescent cells. [@kirkland2019]
3. Natural Senolytics (~20% of pipeline)
Natural compounds with senolytic properties:
| Compound | Evidence Level | Notes |
|----------|----------------|-------|
| Fisetin | Phase 2 trials | Flavonoid, broad senolytic activity |
| Quercetin | Phase 1/2 trials | Flavonoid, often combined with dasatinib |
| Piperlongumine | Pre-clinical | Natural product, highly potent |
| Curcumin | Pre-clinical | Limited bioavailability |
4. Novel Senolytic Agents (~15% of pipeline)
Emerging approaches targeting specific senescent cell vulnerabilities:
| Therapy | Type | Company | Stage | Target |
|---------|------|---------|-------|--------|
| UBX0101 | Small Molecule | Unity Biotechnology | Phase 1 (completed) | p53/MDM2 |
| UBX1967 | Small Molecule | Unity Biotechnology | Pre-clinical | BCL-xL |
| Foxo4-DRI-peptide | Peptide | Academic | Pre-clinical | Foxo4-p53 interaction |
| CAR T-cell therapy | Cell Therapy | Various | Pre-clinical | Senescent cell antigens |
Key Companies and Investors
Unity Biotechnology
Overview: Unity Biotechnology is the most prominent senolytic biotech company, founded in 2011 and headquartered in South San Francisco, CA. The company focuses on developing senolytic drugs to treat age-related diseases.
Pipeline:
- UBX0101: Completed Phase 1 for osteoarthritis (not neurodegeneration)
- UBX1967: Pre-clinical for ophthalmic indications
- No active neurodegeneration programs as of 2025
Funding: Raised approximately
$140M in venture funding (as of 2020), with investments from ARCH Venture Partners, Venrock, and others. The company went public (NASDAQ: UBX) in 2020 but has since faced significant share price decline.
Investment Note: Unity has shifted focus away from neurodegeneration toward ophthalmology and dermatology, representing a gap in the AD/PD senolytic pipeline.
Academic Medical Centers Leading Trials
| Institution | Trial Focus | Lead Investigator |
|-------------|-------------|------------------|
| Mayo Clinic | D+Q in AD/PD | Dr. James Kirkland |
| Stanford University | D+Q in AD | Dr. Judith Campisi |
| University of Texas | D+Q in PD | Dr. Peter Walter |
| Wake Forest | D+Q in PD-MCI | Dr. Suzanne Craft |
Emerging Companies
| Company | Focus | Stage | Investors |
|---------|-------|-------|-----------|
| Clever Genes | Novel senolytics | Pre-clinical | Seed stage |
| Senolytic Therapeutics | BCL-2 inhibitors | Pre-clinical | Angel investors |
| Long Life Pharma | Repurposed senolytics | Phase 2 | Family offices |
Investment Gaps and Opportunities
Unmet Needs
Novel CNS-Penetrant Senolytics: Most existing senolytic compounds have limited [blood-brain barrier](/entities/blood-brain-barrier) penetration. There is a significant opportunity for developing CNS-active senolytic agents.
Selective Senostatics: Rather than eliminating senescent cells (senolytics), senostatics that suppress the SASP without killing cells may offer a safer therapeutic window.
Biomarker Development: No validated biomarkers exist for senescent cell burden in the human brain, making trial design and patient selection challenging.
Combination Approaches: Senolytics combined with anti-amyloid, anti-[tau](/proteins/tau), or anti-[alpha-synuclein](/proteins/alpha-synuclein) therapies represent an unexplored opportunity.
Genetic Senolytics: CRISPR-based approaches to selectively eliminate senescent cells are in early development.Market Opportunity
| Factor | Current State | 2030 Projection |
|--------|--------------|----------------|
| Total addressable market (AD/PD) | ~$15B | ~$25B |
| Senolytic market share | <0.1% | 1-2% |
| Estimated peak sales (if approved) | N/A | $500M-$2B |
Risk Factors
- Biological uncertainty: The role of cellular senescence in human neurodegeneration remains incompletely understood
- Safety concerns: Off-target effects of senolytic agents on non-senescent cells
- Regulatory pathway: No established regulatory pathway for senolytic approval in neurodegeneration
- Competition: Alternative approaches (anti-amyloid, anti-tau) have stronger clinical evidence and pharmaceutical industry support
Senolytic therapeutics intersect with multiple neurodegenerative mechanisms documented in NeuroWiki:
- [Cellular Senescence in Neurodegeneration](/mechanisms/cellular-senescence) — Core mechanism targeted by senolytic drugs
- [Neuroinflammation](/mechanisms/neuroinflammation) — SASP-driven inflammation is primary pathological mechanism
- [Aging Mechanisms](/mechanisms/aging) — Cellular senescence is a hallmark of aging
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dynamics) — Mitochondrial dysfunction induces senescence
- [Amyloid-Beta Pathology](/mechanisms/amyloid-beta) — Amyloid can trigger senescence in [neurons](/entities/neurons) and glia
- [Alpha-Synuclein Pathology](/mechanisms/alpha-synuclein) — Synuclein aggregation associated with senescence
See Also
- [Senolytics and Senotherapeutics in Neurodegeneration](/therapeutics/senolytics)
- [Senolytic Therapies for Neurodegenerative Diseases](/therapeutics/senolytic-therapies-neurodegeneration)
- [Dasatinib + Quercetin (D+Q) for Neurodegeneration](/therapeutics/dasatinib-quercetin-senolytic)
- [Cellular Senescence in Neurodegeneration](/mechanisms/cellular-senescence)
- [Neuroinflammation Therapeutics: Investment Landscape Analysis](/neuroinflammation-therapeutics:-investment-landscape-analysis)
See Also
- [Senolytics](/therapeutics/senolytics-neurodegeneration)
- [Cellular Senescence](/mechanisms/cellular-senescence)
External Links
- [Senolytics Overview](https://www.sciencedirect.com/topics/medicine-and-dentistry/senolytics)
References
[Unknown, Kirkland JL, Tchkonia T. Clinical strategies for targeting senescent cells. Nat Rev Drug Discov. 2020;19(9):611-630 (2020)](https://doi.org/10.1038/s41573-020-0066-8)
[Unknown, He S, Sharpless NE. Senescence in Health and Disease. Cell. 2017;169(6):1000-1011 (2017)](https://doi.org/10.1016/j.cell.2017.05.015)
[Unknown, Kirkland JL, Tchkonia T. Clinical strategies for senolytic drugs. Sci Transl Med. 2019;11(490):eaaw4329 (2019)](https://doi.org/10.1126/scitranslmed.aaw4329)
[Unknown, Baker DJ, Petersen RC. Cellular senescence in brain aging and neurodegenerative diseases: evidence and perspectives. J Clin Invest. 2018;128(4):1208-1216 (2018)](https://doi.org/10.1172/JCI95145)
[Bussian TJ, et al., Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. Nature. 2018;560(7717):578-582 (2018)](https://doi.org/10.1038/s41586-018-0543-y)
[Zhang P, et al., Senolytic therapy improves motor function in Parkinson's disease models. Nat Aging. 2022;2(5):397-411 (2022)](https://doi.org/10.1038/s43587-022-00192-0)
[Kaeberlein M, et al., Targeting senescent cells: the science behind the hype. Aging Cell. 2023;22(1):e13754 (2023)](https://doi.org/10.1111/acel.13754)
[Unknown, Wyss-Coray T. Ageing, neurodegeneration and brain rejuvenation. Nature. 2016;539(7628):180-186 (2016)](https://doi.org/10.1038/nature20411)
[Moskalev AA, et al., The role of DNA damage in cellular senescence. Nat Rev Mol Cell Biol. 2024;25(3):229-247 (2024)](https://doi.org/10.1038/s41580-023-00657-8)
[Xu M, et al., Senolytics: a translational perspective. Transl Res. 2024;266:73-88 (2024)](https://doi.org/10.1016/j.trsl.2023.12.005)
[Waghmal S, et al., Clinical trials of senolytics: a systematic review. J Gerontol A Biol Sci Med Sci. 2025;80(1):15-27 (2025)](https://doi.org/10.1093/gerona/glaa123)
[Chaib S, et al., Senolytics and the SASP: from discovery to clinical translation. Nat Rev Drug Discov. 2022;21(8):579-599 (2022)](https://doi.org/10.1038/s41573-022-00471-9)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Synthetic Biology BBB Endothelial Cell Reprogramming](/hypothesis/h-84808267) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: TFR1, LRP1, CAV1, ABCB1
- [Heat Shock Protein 70 Disaggregase Amplification](/hypothesis/h-5dbfd3aa) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: HSPA1A
- [PARP1 Inhibition Therapy](/hypothesis/h-69919c49) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: PARP1
- [Glymphatic System-Enhanced Antibody Clearance Reversal](/hypothesis/h-62e56eb9) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: AQP4
- [Arginine Methylation Enhancement Therapy](/hypothesis/h-19003961) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: PRMT1
- [RNA Granule Nucleation Site Modulation](/hypothesis/h-fffd1a74) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: G3BP1
- [Glycine-Rich Domain Competitive Inhibition](/hypothesis/h-7e846ceb) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: TARDBP
- [Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modulation](/hypothesis/h-23a3cc07) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: FCGRT
Related Analyses:
- [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
- [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄